Tumor-derived IL-6 may contribute to the immunological defect in CLL Leukemia (2008) Chronic lymphocytic leukemia (CLL) is an indolent disorder with a highly variable course whose clinical features arise through the accumulation of tumor cells in the bone marrow, blood and secondary lymphoid tissue. While hematopoietic failure may occur in those with advanced disease, for the majority it is immune dysfunction, manifested as susceptibility to infection or autoimmunity, which dominates the clinical picture. Both the disease and its treatment may affect the number of normal cells in the innate and adaptive immune systems, however, it is clear that there are also more subtle qualitative defects which presumably arise either through contact with the expanded neoplastic B cell compartment or because of the secretion of immunomodulatory cytokines. A variety of functional defects in T cells from patients with CLL have been reported including, reduction in activation-induced CD40L expression 1 and abnormalities of gene expression affecting the differentiation of CD4 cells and cytoskeletal function and vesicle transport in CD8 cells. 2 Although these abnormalities were shown to arise through contact with the malignant clone it is clear that soluble mediators may also play a role, as we have previously shown in myeloid malignancies. 3 In the present study, we sought to characterize and identify soluble immunomodulatory factors in CLL since these might lend themselves to therapeutic intervention.
We first determined the contribution of soluble mediators to the abnormal mixed lymphocyte reaction (MLR) observed in CLL patients. Tumor supernatant (TSN) was generated from resting CLL cells incubated at 5 Â 10 6 -5 Â 10 7 ml À1 in complete media (CM) comprising RPMI supplemented with 10% fetal calf serum, penicillin-streptomycin, L-glutamine and 1% bovine serum albumin. At the end of the culture period the viability of the CLL cells was always in excess of 70%. Supernatants were harvested by centrifugation at 400g for 10 min and filtered through a 0.2 mm filter. The same conditions were used for normal peripheral blood mononuclear cells (PBMNCs), B cells and the Daudi B cell line. TSN was added to an allogeneic MLR between unrelated donors randomly chosen from a panel of 12 normal individuals from which 9 separate donor/responder pairs were selected. Inhibition of [ 3 H]thymidine incorporation was observed after 5 days in 9/9 cultures containing TSN (paired t-test, P ¼ 0.0002, Figure 1a ). Since these results suggested that TSN inhibits T cell proliferation, we next determined its effect on cell cycle entry and division in response to stimulation with CD3 and CD28 agonistic antibodies. T cells from normal donors were activated with anti-CD3/CD28 beads for 72 h in the presence or absence of TSN and then fixed with ice-cold ethanol. Following RNAse treatment and staining with propidium iodide, their DNA content was measured by flow cytometry. In the presence of TSN there was a reduction in the proportion of cells in S/G 2 M from a mean of 22.7 ± 0.7-12.8 ± 0.9% (P ¼ 0.0096, n ¼ 3, Figure 1b ). Experiments performed using carboxy fluorescein succinimidyl ester labeled normal T cells showed that TSN reduced the number of T cells undergoing one or more cell divisions from a mean of 81.0 ± 1.0-52.0 ± 11% (P ¼ 0.02, n ¼ 3, Figure 1c) .
Next, we examined the effect of CLL TSN on the upregulation of CD40L expression and Interleukin-2 (IL-2) secretion; two key aspects of T cell activation. Incubation of normal CD3 þ T cells in TSN for 12 h prior to activation with phorbol ester and ionomycin reduced CD40L expression to 51 ± 5.6% (range ¼ 14-86%, n ¼ 17, Po0.0001) of that observed in CM (example shown in Figure 2a ). This occurred regardless of whether CLL cells were purified prior to collection of TSN indicating that the effect was due to factor(s) derived from the tumor and not another cell type (data not shown). There was no correlation between the degree of inhibition of CD40L expression and either CD38 level or immunoglobulin gene mutational status of the CLL cells. Supernatants prepared from normal PBMNCs and the Daudi B cell line had no effect (Figure 2a ). When TSN was prepared from normal PBMNCs that had been partially T cell depleted using immunomagnetic beads to reproduce the conditions of high B cell density observed in CLL, viability at the end of the collection period was always o50%. Supernatant collected from these normal B cell cultures consistently caused normal T cells to undergo apoptosis and further experiments using this material were therefore not performed. In contrast, CLL-derived TSN appeared to promote the survival of normal T cells.
In addition to its effect on activation-induced expression of CD40L, TSN from all 17 CLL cases also inhibited IL-2 production by normal T cells. The effects of TSN on CD40L level and IL-2 secretion varied from patient to patient and were broadly correlated ( Figure 2b , P ¼ 0.008, r 2 ¼ 0.52), suggesting involvement of the same factor(s). Inhibition of CD40L expression by TSN also paralleled its inhibitory effects on the allogeneic MLR as a significant correlation was observed between the inhibition of CD40L expression after 24 h and [
3 H]thymidine incorporation at 5 days in an MLR (P ¼ 0.0002, r 2 ¼ 0.56, n ¼ 9). CLL cells thus secrete soluble mediator(s) that inhibit both the activation and proliferation of normal T cells. Since these results were at variance with a previous report suggesting that cell contact and not soluble factors mediate the CD40L abnormality in CLL, 1 we investigated the mechanism of this defect. While contact with CLL cells caused downregulation of CD40L by T cells that had been previously activated, TSN inhibited upregulation during T cell activation. The CD40L defect in CLL patients could be reversed by purification of T cells and removal of contact with tumor cells and their secreted factors proving that there is no intrinsic abnormality of this system in CLL T cells. Since IL-2 is a Th1 cytokine, we next determined whether the reduced secretion observed when T cells are activated in the presence of TSN is associated with a shift to Th2 polarization by measuring the level of the Th2 cytokine Interleukin-4 (IL-4). Normal T cells activated by ligation of CD3/CD28 beads in the presence of TSN produced 7-10-fold more IL-4, to a mean of 4.3 ng ml À1 ( ± 0.405) at 72 h, compared to T cells activated in the CM control. Although TSN itself contained measurable amounts of IL-4, the levels present at the end of the T cell activation period were 10-fold higher than those initially present (Figure 3a) .
To identify the factor(s) which might be responsible for the observed effects of TSN on T cell activation and polarization, we next performed cytokine bead array assays for IL-2, g-interferon, tumor necrosis factor-a, Interleukin-10, IL-4 and Interleukin-6 (IL-6) and enzyme-linked immunoassays for transforming growth factor-b and soluble IL-2 receptor (CD25). The levels of IL-6 in TSN were 485 ng ml À1 in all cases studied (n ¼ 5). The remaining cytokines were consistently present at o0.5 ng ml À1 except g-interferon, which was found in 2/5 cases at 1.5 and 3.0 ng ml
À1
. Soluble CD25 levels were undetectable. To confirm that the CLL cells were the predominant source of the IL-6, PBMNCs from CLL patients were cultured in a resting state for 16 h in the presence of Brefeldin A. Cells were then fixed, permeabilized and stained with FITC-anti-CD19 and either PE-anti-IL-6 or a PE-conjugated isotype-matched control and analyzed by flow cytometry. The FITC-positive CD19 cells were gated and the PE-MFI of the isotype-matched control compared to that of the anti-IL-6. Although there was some IL-6 production by CD19 negative cells, CD19-positive CLL cells produced-enough IL-6 to double the mean fluorescence intensity compared to the isotype-matched control confirming that the tumor is the predominant source of this cytokine (Figure 3b) . 
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Having shown that CLL cells secrete IL-6, we went on to determine whether this factor might be responsible for some of the inhibitory effects on normal T cells. TSN from six patients was depleted of IL-6 using anti-IL-6 conjugated to sepharose beads. In all but two cases, it proved impossible to deplete IL-6 levels to less than 50% of the original concentration. When normal T cells were activated in the presence of TSN depleted to 36 and 24% of the original IL-6 level there was an increase in Tcell IL-2 production (data not shown) and CD40L upregulation compared to unmodified TSN (Figure 4a) . Since, it proved impossible to fully deplete TSN of IL-6 further experiments were performed using an IL-6 receptor-blocking antibody. Addition of this reagent to normal T cells prior to incubation with CLL TSN restored CD40L expression from a mean of 41±4.3-63±4.3% of that observed in CM (Figure 4b , n ¼ 6, P ¼ 0.0067). The addition of recombinant IL-6 to CM at similar concentrations to that found in TSN (100 ng ml À1 ) inhibited both IL-2 production (data not shown) and CD40L upregulation by activated normal T cells (Figure 4c) .
In this study, we have shown that CLL cells secrete factor(s) that inhibit the activation and proliferation of normal T cells and cause secretion of IL-4, the prototypic Th2 cytokine. Although CLL cells are known to be capable of secreting numerous cytokines, 4 in our system, IL-6 was the predominant factor detected. Removal or blockade of IL-6 signaling reversed the effects of medium conditioned by the tumor on T cell activation while addition of the recombinant cytokine at the same concentration reproduced the findings.
IL-6 is a pleiotropic cytokine with effects on hematopoiesis, B cell differentiation and the systemic inflammatory response, causing fever and the production of acute-phase proteins by the liver. 5 Secretion of IL-6 by antigen-presenting cells also has important effects on T cell differentiation by reciprocally regulating IL-2 and IL-4 secretion and promoting Th2 polarization. 6 In addition to its effects on normal cells, IL-6 also contributes to the pathogenesis of a number of inflammatory and malignant conditions including Crohn's disease, systemic idiopathic juvenile arthritis and rheumatoid arthritis as well as a number of other disorders. Our findings suggest that CLL should now be added to this list and are in keeping with reports that elevated serum levels of this cytokine correlate with advanced disease and adverse outcome. 7, 8 It is now clear that bi-directional interactions between various non-neoplastic stromal and immune cells and the tumor are crucially important both for the maintenance and progression of the malignant clone in CLL and the induction of immune dysfunction that is such a hallmark of the disease. 2 The results presented here have several implications for understanding these aspects of CLL pathogenesis. Firstly, IL-6 or secondary cytokines may promote disease progression either directly through effects on cell survival and proliferation or indirectly through effects on the microenvironment, for example, by causing T cells to secrete IL-4 or through IL-6-induced VEGFmediated neovascularization. In addition, IL-6 may contribute to the complex immunopathology of CLL through its inhibitory effects on T cell activation, the CD40L system and induction of a Th2 cytokine response, which may lead to defective cellular and humoral immunity and a propensity to autoimmunity. As well as its potential effects on the tumor and normal immune system, IL-6 is an important inflammatory mediator and induces fever and the acute-phase response. Advanced CLL is frequently associated with fever and lethargy and elevated IL-6 levels might thus play a role in this troublesome constellation of symptoms. Finally, our findings are of potential relevance to the treatment of CLL since blockade of IL-6 signaling, either by neutralizing or receptor blocking agents, might slow disease progression and reduce the systemic symptoms and immune dysfunction that are such a central feature of CLL.
